1. Yu. V. Burov, S. E. Metkalova, A. É. Kustov, G. V. Petrov, and V. V. Shul’govskii, “The effects of amiridine on MPTP-induced Parkinson-like syndrome in monkeys,” Byull. Éksp. Biol. Med.,11, 495–497 (1992).
2. Yu. V. Burov, V. V. Shul’govskii, G. V. Petrov, L. V. Tereshchenko, and A. G. Yudin, “Disturbances in operant behavior in MPTP-induced Parkinson-like syndrome,” Fiziol. Zh. im. I. M. Sechenova.,81, No. 10, 109–112 (1995).
3. R. S. Burns, C. C. Chiueh, S. P. Markey, M. H. Ebert, D. M. Jacobowitz, and I. J. Kopin, “A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by MPTP,” Proc. Natl. Acad. Sci. USA,80, 4546–4550 (1983).
4. C. E. Clarke, M. A. Sambrook, I. J. Mitchell, and A. R. Crossman, “L-DOPA-induced dyskinesia and response fluctuations in primates rendered parkinsonian with MPTP,” J. Neurol. Sci.,78, No. 3, 273–280 (1987).
5. J. S. Schneider, G. Unguez, A. Yuwiler, S. C. Berg, and C. H. Markham, “Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Brain,111, 1265–1285 (1988)